Production of human monoclonal antibodies: potential therapeutic use in gut-derived infectious-toxic shock syndromes.
Waelti
E R
ER
Institute of Pathology, University of Bern, Switzerland.
Stucki
M
M
D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000302:isolation & purification* / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D002460:Cell Line; D004274:DNA, Recombinant; D004731:Endotoxins / Q000009:adverse effects / Q000276:immunology; D006090:Gram-Negative Bacteria / Q000276:immunology; D004854:Herpesvirus 4, Human; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007422:Intestines / Q000382:microbiology*; D051379:Mice; D009101:Multiple Myeloma / Q000473:pathology; D015202:Protein Engineering; D012772:Shock, Septic / Q000517:prevention & control / Q000628:therapy*; D013045:Species Specificity; D014407:Tumor Cells, Cultured
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D004274:DNA, Recombinant; D004731:Endotoxins